1
Great Britain. Audit Commission for Local Authorities and the National Health Service in England and Wales. What Seems to Be the Matter Communication (National Health Service Report). Stationery Office https://webarchive.nationalarchives.gov.uk/20150410163038/http://archive.audit-commission.gov.uk/auditcommission/aboutus/publications/pages/national-reports-and-studies-archive.aspx.html
2
An information leaflet for surgical patients. Annals of The Royal College of Surgeons of England 1983;65.https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2494353/
3
Department of Health. Toolkit for Producing Patient Information, Version 2. 2003.https://www.uea.ac.uk/documents/246046/0/Toolkit+for+producing+patient+information.pdf
4
Garner M, Ning Z, Francis J. A framework for the evaluation of patient information leaflets. Health Expectations 2012;15:283–94. doi:10.1111/j.1369-7625.2011.00665.x
5
Prescription information leaflets: a pilot study in general practice. British Medical Journal (Clinical research ed) 1983;287.https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1549423/
6
Berthelsen MP, Husu E, Christensen SB, et al. Anti-gravity training improves walking capacity and postural balance in patients with muscular dystrophy. Neuromuscular Disorders 2014;24:492–8. doi:10.1016/j.nmd.2014.03.001
7
Cup EH, Pieterse AJ, ten Broek-Pastoor JM, et al. Exercise Therapy and Other Types of Physical Therapy for Patients With Neuromuscular Diseases: A Systematic Review. Archives of Physical Medicine and Rehabilitation 2007;88:1452–64. doi:10.1016/j.apmr.2007.07.024
8
Voet NB, van der Kooi EL, Riphagen II, et al. Strength training and aerobic exercise training for muscle disease. Cochrane Database of Systematic Reviews Published Online First: 9 July 2013. doi:10.1002/14651858.CD003907.pub4
9
Sveen M-L, Andersen SP, Ingelsrud LH, et al. Resistance training in patients with limb-girdle and becker muscular dystrophies. Muscle & Nerve 2013;47:163–9. doi:10.1002/mus.23491
10
Jeppesen TD, Schwartz M, Olsen DB, et al. Aerobic training is safe and improves exercise capacity in patients with mitochondrial myopathy. Brain 2006;129:3402–12. doi:10.1093/brain/awl149
11
Balance and walking involvement in facioscapulohumeral dystrophy: a pilot study on the effects of custom lower limb orthoses - European Journal of Physical and Rehabilitation Medicine 2013 April;49(2):169-78 - Minerva Medica - Journals. https://www.minervamedica.it/en/journals/europa-medicophysica/article.php?cod=R33Y2013N02A0169
12
Institute of Neurology, Queen Square, National Hospital for Neurology and Neurosurgery (London, England). Neurology: a Queen Square textbook. Second edition. Chichester, West Sussex, UK: : John Wiley & Sons, Inc 2016. https://onlinelibrary.wiley.com/doi/book/10.1002/9781118486160
13
Neuromuscular Disease Center. https://neuromuscular.wustl.edu/
14
Barohn RJ, Dimachkie MM, Jackson CE. A Pattern Recognition Approach to Patients with a Suspected Myopathy. Neurologic Clinics 2014;32:569–93. doi:10.1016/j.ncl.2014.04.008
15
Jones DA, Haan A de, Round JM. Skeletal muscle from molecules to movement: a textbook of muscle physiology for sport, exercise, physiotherapy and medicine. Edinburgh: : Churchill Livingstone 2004.
16
By:Gordon, AM (Gordon, AM); Homsher, E (Homsher, E); Regnier, M (Regnier, M). Regulation of contraction in striated muscle. PHYSIOLOGICAL REVIEWS PHYSIOLOGICAL REVIEWS 2000;80:853–924.http://apps.webofknowledge.com/full_record.do?product=WOS&search_mode=GeneralSearch&qid=13&SID=C49BOGnSGP9s3PqA3ow&page=1&doc=1
17
Force-velocity properties of human skeletal muscle fibres: myosin heavy chain isoform and temperature dependence. The Journal of Physiology 1996;495.https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1160815/
18
Harridge SDR, Bottinelli R, Canepari M, et al. Whole-muscle and single-fibre contractile properties and myosin heavy chain isoforms in humans. Pflügers Archiv - European Journal of Physiology 1996;432:913–20. doi:10.1007/s004240050215
19
Hunter S, White M, Thompson M. Techniques to Evaluate Elderly Human Muscle Function: A Physiological Basis. The Journals of Gerontology Series A: Biological Sciences and Medical Sciences 1998;53A:B204–16. doi:10.1093/gerona/53A.3.B204
20
O’Brien TD, Reeves ND, Baltzopoulos V, et al. In vivo measurements of muscle specific tension in adults and children. Experimental Physiology 2010;95:202–10. doi:10.1113/expphysiol.2009.048967
21
Atherton PJ, Smith K. Muscle protein synthesis in response to nutrition and exercise. The Journal of Physiology 2012;590:1049–57. doi:10.1113/jphysiol.2011.225003
22
Baar K. Using Molecular Biology to Maximize Concurrent Training. Sports Medicine 2014;44:117–25. doi:10.1007/s40279-014-0252-0
23
Rennie MJ, Wackerhage H, Spangenburg EE, et al. Control of the Size of the Human Muscle Mass. Annual Review of Physiology 2004;66:799–828. doi:10.1146/annurev.physiol.66.052102.134444
24
Kadi F. Cellular and molecular mechanisms responsible for the action of testosterone on human skeletal muscle. A basis for illegal performance enhancement. British Journal of Pharmacology 2008;154:522–8. doi:10.1038/bjp.2008.118
25
Velloso CP. Regulation of muscle mass by growth hormone and IGF-I. British Journal of Pharmacology 2008;154:557–68. doi:10.1038/bjp.2008.153
26
Marcotte GR, West DWD, Baar K. The Molecular Basis for Load-Induced Skeletal Muscle Hypertrophy. Calcified Tissue International 2015;96:196–210. doi:10.1007/s00223-014-9925-9
27
Egner IM, Bruusgaard JC, Eftestøl E, et al. A cellular memory mechanism aids overload hypertrophy in muscle long after an episodic exposure to anabolic steroids. The Journal of Physiology 2013;591:6221–30. doi:10.1113/jphysiol.2013.264457
28
Atherton PJ, Smith K. Muscle protein synthesis in response to nutrition and exercise. The Journal of Physiology 2012;590:1049–57. doi:10.1113/jphysiol.2011.225003
29
Fitts RH, Trappe SW, Costill DL, et al. Prolonged space flight-induced alterations in the structure and function of human skeletal muscle fibres. The Journal of Physiology 2010;588:3567–92. doi:10.1113/jphysiol.2010.188508
30
By:Jones, SW (Jones, SW); Hill, RJ (Hill, RJ); Krasney, PA (Krasney, PA); O’Conner, B (O’Conner, B); Peirce, N (Peirce, N); Greenhaff, PL (Greenhaff, PL). Disuse atrophy and exercise rehabilitation in humans profoundly affects the expression of genes associated with the regulation of skeletal muscle mass. FASEB JOURNAL FASEB JOURNAL 2004;18. doi:10.1096/fj.03-1228fje
31
Rennie MJ, Wackerhage H, Spangenburg EE, et al. Control of the Size of the Human Muscle Mass. Annual Review of Physiology 2004;66:799–828. doi:10.1146/annurev.physiol.66.052102.134444
32
Shavlakadze T, Grounds M. Of bears, frogs, meat, mice and men: complexity of factors affecting skeletal muscle mass and fat. BioEssays 2006;28:994–1009. doi:10.1002/bies.20479
33
Puthucheary ZA, Rawal J, McPhail M, et al. Acute Skeletal Muscle Wasting in Critical Illness. JAMA 2013;310. doi:10.1001/jama.2013.278481
34
Wiggs MP. Can endurance exercise preconditioning prevention disuse muscle atrophy? Frontiers in Physiology 2015;6. doi:10.3389/fphys.2015.00063
35
Baar K. Using Molecular Biology to Maximize Concurrent Training. Sports Medicine 2014;44:117–25. doi:10.1007/s40279-014-0252-0
36
Craig DM, Ashcroft SP, Belew MY, et al. Utilizing small nutrient compounds as enhancers of exercise-induced mitochondrial biogenesis. Frontiers in Physiology 2015;6. doi:10.3389/fphys.2015.00296
37
Hoier B, Hellsten Y. Exercise-Induced Capillary Growth in Human Skeletal Muscle and the Dynamics of VEGF. Microcirculation 2014;21:301–14. doi:10.1111/micc.12117
38
Hardie DG, Sakamoto K. AMPK: A Key Sensor of Fuel and Energy Status in Skeletal Muscle. Physiology 2006;21:48–60. doi:10.1152/physiol.00044.2005
39
Hawley JA, Hargreaves M, Joyner MJ, et al. Integrative Biology of Exercise. Cell 2014;159:738–49. doi:10.1016/j.cell.2014.10.029
40
Briggs D, Morgan JE. Recent progress in satellite cell/myoblast engraftment - relevance for therapy. FEBS Journal 2013;280:4281–93. doi:10.1111/febs.12273
41
Zammit PS, Golding JP, Nagata Y, et al. Muscle satellite cells adopt divergent fates. The Journal of Cell Biology 2004;166:347–57. doi:10.1083/jcb.200312007
42
Boldrin L, Morgan JE. Activating muscle stem cells: therapeutic potential in muscle diseases. Current Opinion in Neurology 2007;20:577–82. doi:10.1097/WCO.0b013e3282ef5919
43
Boldrin L, Zammit PS, Morgan JE. Satellite cells from dystrophic muscle retain regenerative capacity. Stem Cell Research 2015;14:20–9. doi:10.1016/j.scr.2014.10.007
44
Ross J, Benn A, Jonuschies J, et al. Defects in Glycosylation Impair Satellite Stem Cell Function and Niche Composition in the Muscles of the Dystrophic Large Mouse. STEM CELLS 2012;30:2330–41. doi:10.1002/stem.1197
45
Neuropathology and Applied Neurobiology. ;Volume 43, Issue 1.https://onlinelibrary.wiley.com/toc/13652990/2017/43/1
46
Dubowitz V, Sewry CA, Oldfors A. Muscle biopsy: a practical approach. Fourth edition. [Philadelphia, Pa.]: : Saunders Elsevier 2013.
47
Hollingsworth KG, de Sousa PL, Straub V, et al. Towards harmonization of protocols for MRI outcome measures in skeletal muscle studies: Consensus recommendations from two TREAT-NMD NMR workshops, 2 May 2010, Stockholm, Sweden, 1–2 October 2009, Paris, France. Neuromuscular Disorders 2012;22:S54–67. doi:10.1016/j.nmd.2012.06.005
48
Wattjes MP, Fischer D. Neuromuscular imaging. New York: : Springer 2013. http://ucl.alma.exlibrisgroup.com/view/action/uresolver.do?operation=resolveService&package_service_id=3320980190004761&institutionId=4761&customerId=4760
49
Forbes SC, Willcocks RJ, Triplett WT, et al. Magnetic Resonance Imaging and Spectroscopy Assessment of Lower Extremity Skeletal Muscles in Boys with Duchenne Muscular Dystrophy: A Multicenter Cross Sectional Study. PLoS ONE 2014;9. doi:10.1371/journal.pone.0106435
50
Glover GH, Schneider E. Three-point dixon technique for true water/fat decomposition withB0 inhomogeneity correction. Magnetic Resonance in Medicine 1991;18:371–83. doi:10.1002/mrm.1910180211
51
Willcocks RJ, Rooney WD, Triplett WT, et al. Multicenter prospective longitudinal study of magnetic resonance biomarkers in a large duchenne muscular dystrophy cohort. Annals of Neurology 2016;79:535–47. doi:10.1002/ana.24599
52
Hogrel J-Y, Wary C, Moraux A, et al. Longitudinal functional and NMR assessment of upper limbs in Duchenne muscular dystrophy. Neurology 2016;86:1022–30. doi:10.1212/WNL.0000000000002464
53
Kim HK, Serai S, Lindquist D, et al. Quantitative Skeletal Muscle MRI: Part 2, MR Spectroscopy and T2 Relaxation Time Mapping—Comparison Between Boys With Duchenne Muscular Dystrophy and Healthy Boys. American Journal of Roentgenology 2015;205:W216–23. doi:10.2214/AJR.14.13755
54
Muntoni F, Torelli S, Ferlini A. Dystrophin and mutations: one gene, several proteins, multiple phenotypes. The Lancet Neurology 2003;2:731–40. doi:10.1016/S1474-4422(03)00585-4
55
Bushby K, Finkel R, Birnkrant DJ, et al. Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and pharmacological and psychosocial management. The Lancet Neurology 2010;9:77–93. doi:10.1016/S1474-4422(09)70271-6
56
Bushby K, Finkel R, Birnkrant DJ, et al. Diagnosis and management of Duchenne muscular dystrophy, part 2: implementation of multidisciplinary care. The Lancet Neurology 2010;9:177–89. doi:10.1016/S1474-4422(09)70272-8
57
Ricotti V, Ridout DA, Scott E, et al. Long-term benefits and adverse effects of intermittent versus daily glucocorticoids in boys with Duchenne muscular dystrophy. Journal of Neurology, Neurosurgery & Psychiatry 2013;84:698–705. doi:10.1136/jnnp-2012-303902
58
Goemans NM, Tulinius M, van den Akker JT, et al. Systemic Administration of PRO051 in Duchenne’s Muscular Dystrophy. New England Journal of Medicine 2011;364:1513–22. doi:10.1056/NEJMoa1011367
59
Mendell JR, Rodino-Klapac LR, Sahenk Z, et al. Eteplirsen for the treatment of Duchenne muscular dystrophy. Annals of Neurology 2013;74:637–47. doi:10.1002/ana.23982
60
Mendell JR, Goemans N, Lowes LP, et al. Longitudinal effect of eteplirsen versus historical control on ambulation in Duchenne muscular dystrophy. Annals of Neurology 2016;79:257–71. doi:10.1002/ana.24555
61
Kinali M, Arechavala-Gomeza V, Feng L, et al. Local restoration of dystrophin expression with the morpholino oligomer AVI-4658 in Duchenne muscular dystrophy: a single-blind, placebo-controlled, dose-escalation, proof-of-concept study. The Lancet Neurology 2009;8:918–28. doi:10.1016/S1474-4422(09)70211-X
62
Cirak S, Arechavala-Gomeza V, Guglieri M, et al. Exon skipping and dystrophin restoration in patients with Duchenne muscular dystrophy after systemic phosphorodiamidate morpholino oligomer treatment: an open-label, phase 2, dose-escalation study. The Lancet 2011;378:595–605. doi:10.1016/S0140-6736(11)60756-3
63
Bushby K, Finkel R, Wong B, et al. Ataluren treatment of patients with nonsense mutation dystrophinopathy. Muscle & Nerve 2014;50:477–87. doi:10.1002/mus.24332
64
Paganoni S, Amato A. Electrodiagnostic Evaluation of Myopathies. Physical Medicine and Rehabilitation Clinics of North America 2013;24:193–207. doi:10.1016/j.pmr.2012.08.017
65
Fuglsang-Frederiksen A. The role of different EMG methods in evaluating myopathy. Clinical Neurophysiology 2006;117:1173–89. doi:10.1016/j.clinph.2005.12.018
66
Machado P, Brady S, Hanna MG. Update in inclusion body myositis. Current Opinion in Rheumatology 2013;25:763–71. doi:10.1097/01.bor.0000434671.77891.9a
67
Machado PM, Dimachkie MM, Barohn RJ. Sporadic inclusion body myositis. Current Opinion in Neurology 2014;27:591–8. doi:10.1097/WCO.0000000000000129
68
Machado PM, Ahmed M, Brady S, et al. Ongoing Developments in Sporadic Inclusion Body Myositis. Current Rheumatology Reports 2014;16. doi:10.1007/s11926-014-0477-9
69
Ahmed M, Machado PM, Miller A, et al. Targeting protein homeostasis in sporadic inclusion body myositis. Science Translational Medicine 2016;8:331ra41-331ra41. doi:10.1126/scitranslmed.aad4583
70
Needham M, Mastaglia FL. Sporadic inclusion body myositis: A review of recent clinical advances and current approaches to diagnosis and treatment. Clinical Neurophysiology 2016;127:1764–73. doi:10.1016/j.clinph.2015.12.011
71
Schröder R, Schoser B. Myofibrillar Myopathies: A Clinical and Myopathological Guide. Brain Pathology 2009;19:483–92. doi:10.1111/j.1750-3639.2009.00289.x
72
Amato AA, Greenberg SA. Inflammatory Myopathies. CONTINUUM: Lifelong Learning in Neurology 2013;19:1615–33. doi:10.1212/01.CON.0000440662.26427.bd
73
Olivé M, Kley RA, Goldfarb LG. Myofibrillar myopathies. Current Opinion in Neurology 2013;26:527–35. doi:10.1097/WCO.0b013e328364d6b1
74
Carstens P-O, Schmidt J. Diagnosis, pathogenesis and treatment of myositis: recent advances. Clinical & Experimental Immunology 2014;175:349–58. doi:10.1111/cei.12194
75
Dalakas MC. Inflammatory Muscle Diseases. New England Journal of Medicine 2015;372:1734–47. doi:10.1056/NEJMra1402225
76
Darras BT, De Vivo DC, Jones HR. Neuromuscular disorders of infancy, childhood, and adolescence: a clinician’s approach. Philadelphia, Penn. ; London: : Butterworth-Heinemann 2003.
77
Baioni MTC, Ambiel CR. Spinal muscular atrophy: diagnosis, treatment and future prospects. Jornal de Pediatria 2010;86:261–70. doi:10.2223/JPED.1988
78
Rudnik-Schöneborn S, Hausmanowa-Petrusewicz I, Borkowska J, et al. The Predictive Value of Achieved Motor Milestones Assessed in 441 Patients with Infantile Spinal Muscular Atrophy Types II and III. European Neurology 2001;45:174–81. doi:10.1159/000052118
79
Russman BS, Buncher CR, White M, et al. Function changes in spinal muscular atrophy II and III. Neurology 1996;47:973–6. doi:10.1212/WNL.47.4.973
80
Wang CH, Finkel RS, Bertini ES, et al. Consensus Statement for Standard of Care in Spinal Muscular Atrophy. Journal of Child Neurology 2007;22:1027–49. doi:10.1177/0883073807305788
81
Mercuri E, Bertini E, Iannaccone ST. Childhood spinal muscular atrophy: controversies and challenges. The Lancet Neurology 2012;11:443–52. doi:10.1016/S1474-4422(12)70061-3
82
Hollak CEM, Lachmann R, editors. Inherited Metabolic Disease in Adults. Oxford University Press 2016. doi:10.1093/med/9780199972135.001.0001
83
Nancy D Leslie. Very Long-Chain Acyl-Coenzyme A Dehydrogenase Deficiency. Gene Reviews Published Online First: 2018.https://www.ncbi.nlm.nih.gov/books/NBK6816/
84
Thomas Wieser. Carnitine Palmitoyltransferase II Deficiency. Gene Reviews Published Online First: 2017.https://www.ncbi.nlm.nih.gov/books/NBK1253/
85
Miguel A Martín. Glycogen Storage Disease Type V. Gene Reviews Published Online First: 2014.https://www.ncbi.nlm.nih.gov/books/NBK1344/
86
Nancy Leslie. Pompe Disease. Gene Reviews Published Online First: 2017.https://www.ncbi.nlm.nih.gov/books/NBK1261/
87
Ørngreen MC, Vissing J. Treatment Opportunities in Patients With Metabolic Myopathies. Current Treatment Options in Neurology 2017;19. doi:10.1007/s11940-017-0473-2
88
Olpin SE, Murphy E, Kirk RJ, et al. The investigation and management of metabolic myopathies. Journal of Clinical Pathology 2015;68:410–7. doi:10.1136/jclinpath-2014-202808
89
Feingold B, Mahle WT, Auerbach S, et al. Management of Cardiac Involvement Associated With Neuromuscular Diseases: A Scientific Statement From the American Heart Association. Circulation 2017;136. doi:10.1161/CIR.0000000000000526
90
Matthews E, Hanna MG. Skeletal muscle channelopathies. In: Hilton-Jones D, Turner MR, eds. Oxford Textbook of Neuromuscular Disorders. Oxford University Press 2014. 316–25. doi:10.1093/med/9780199698073.003.0031
91
Hollak CEM, Lachmann R, editors. Inherited Metabolic Disease in Adults. Oxford University Press 2016. doi:10.1093/med/9780199972135.001.0001
92
Saudubray JM, Baumgartner MR, Walter J, editors. Inborn metabolic diseases: diagnosis and treatment. 6th edition. Berlin: : Springer 2016.
93
Hoffmann GF, Zschocke J, Nyhan WL, editors. Inherited metabolic diseases: a clinical approach. Second edition. Berlin: : Springer 2017.
